SystmOne: Weight Management

Navigate to the CDRC Quality > Weight to locate the weight management reports.

These reports can be used to identify patients to consider for invitation to the NHS Digital Weight Management Programme. This programme supports adults living with obesity who also have a diagnosis of diabetes, hypertension or both, to manage their weight and improve their health.

For Payment Claims the relevant searches for payment under the weight management ES are in CDRC Contracting > Weight Management 

The following searches will identify people who have had an uncoded weight management referral that might be eligible for payment if coded (consider adding this to a batch reporting process).

The payment trigger code for the ES is: Referral to weight management service 

National Institute for Health and Care Excellence (NICE) recommends Tirzepatide (Mounjaro®) for the management of obesity for certain patients. Tirzepatide is a novel dual GIP/GLP-1 receptor agonist recommended for managing obesity alongside a reduced calorie diet and increased physical activity in adults.

These following reports, located in the CDRC Quality > Weight folder will support the identification of patients who are potentially eligible for Tirzepatide, but a full review of the patient record is required. CDRC have developed a visualisation to support this process. See Visualisation below.

Tirzepatide Claims

The following reports located in the CDRC Contracting > Weight Management apply to patients who started Tirzepatide for weight loss under the NENC LES in 25/26.  Practices are eligible to claim for these patients for up to 12 months after they started treatment.  This does not apply to patients started on Tirzepatide in the current financial year

Closing date for submission is the end of the month. The claim form in on GP Teamnet

• Stage 1: Patient initiation payment
• Stage 2: First six monthly monitoring complete (or discontinued before 6^th  review)
• Stage 3: All monitoring completed (or discontinued before 12^th review)
• Stage 4: Discontinuation/Offboarding payment

Visualisation

The “GLP1 Mounjaro Weight Loss Programme – CDRC” visualisation helps the identification process for whether patients are eligible for Tirzepatide (Mounjaro®); patient’s may meet the criteria for intervention however certain tests may have to be taking before initiating this medication.

The first section highlights current likely eligibility information, there is a drop down button which provides further information.

This patient meets the BMI criteria and is hypertensive on treatment. However, this patient has overdue HbA1c and overdue Lipids – so they may become eligible if those checks were done. This screen also identified that this patient has sleep apnoea but does not have a CPAP code.

Once the patients meets the criteria for this programme, you can expand the Obesity Medication Initiation dropdown to show recent blood tests and whether you need to update them. You can also use the buttons on the left-hand side of the screen to complete the GLP1 Eligibility Checklist & the GLP1 Patient Checklist, which runs through all the questions needed for the patient.

The Review section has button to collect Blood Pressure and BMI, weight loss calculator and then review template which asks all the relevant questions (with relevant sections greyed out if not applicable e.g. doesn’t have diabetes).

Reports

Within the CDRC Quality > Weight folder, the following reports provide you with your Obesity and Overweight Prevalence, along with reports to support case finding:

Template

The Weight Detailed – CDRC template shows detailed information as well as a section to help with motivational interviewing for weight management.